Conjugates of tumor necrosis factor inhibitors to functionalized polymers
This document relates to conjugates of TNF inhibitors or derivatives thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.
1. A method of making a TNF inhibitor conjugate, said method comprising reacting a TNF inhibitor with a preparation comprising a water-soluble, non-peptidic, and non-nucleotidic polymer backbone having at least one terminus covalently bonded to a structure of formula (1) under conditions suitable for group M or R to react with said TNF inhibitor:
or a salt thereof,
wherein:
A is the point of covalent bonding to the terminus of the polymer backbone;
O is oxygen;
E is O, wherein O is oxygen;
P is phosphorous;
K is selected from the group consisting of: alkylene, alkyleneoxyalkylene, and oligomeric alkyleneoxyalkylene;
G is selected from the group consisting of: hydrogen, alkoxy, and a hydrophobic separation handle;
Z 1 and Z 2 are independently O;
L is an alkylene;
M is a protected carboxyl moiety;
R is selected from the group consisting of: a protecting group and a hydrophobic separation handle;
R 1 is absent or a hydrophobic separation handle;
wherein no more than one of R, R 1 , and G is a hydrophobic separation handle.
2. The method claim 1 , wherein R is selected from the group consisting of: trityl, monoalkoxytrityl, dialkoxytrityl, pixyl, alkoxypixyl, fluorenylmethyloxycarbonyl, trifluoroacetyl, acetal, and cyclic acetal.
3. The method of claim 1 , wherein R is selected from the group consisting of: N-hydroxysuccinimidyl, p-nitrophenyl, or pentachlorophenyl.
4. The method of claim 1 , wherein said preparation comprises at least 50% by weight of said water-soluble, non-peptidic, and non-nucleotidic polymer backbone having at least one terminus covalently bonded to a structure of formula (1).
5. The method of claim 4 , wherein said preparation comprises at least 98% by weight of said water-soluble, non-peptidic, and non-nucleotidic polymer backbone having at least one terminus covalently bonded to a structure of formula (1).
6. The method of claim 1 , said method further comprising (i) removing the hydrophobic separation handle(s) from said structure of formula (1) and (ii) optionally reacting the compound obtained in step (i) with an activating agent before reacting with said TNF inhibitor.
7. The method of claim 1 , said method further comprising removing the hydrophobic separation handle(s) from said structure of formula (1) after reacting with said TNF inhibitor.
8. The method of claim 1 , wherein said TNF inhibitor is selected from the group consisting of a fusion protein, a monoclonal antibody, and an antibody fragment.
9. The method of claim 1 , wherein said TNF inhibitor is selected from the group consisting of etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab.
10. A conjugate, or a pharmaceutically acceptable salt thereof, comprising a water-soluble, non-peptidic, and non-nucleotidic polymer backbone having at least one terminus covalently bonded to a structure of formula (9):
or a salt thereof,
wherein:
A is the point of covalent bonding to the terminus of the polymer backbone;
O is oxygen;
E is O, wherein O is oxygen;
P is phosphorous;
K is selected from the group consisting of: alkylene, alkyleneoxyalkylene, and oligomeric alkyleneoxyalkylene;
G is selected from the group consisting of: hydrogen, alkoxy, and a hydrophobic separation handle;
Z 1 and Z 2 are independently O;
L is an alkylene;
R 1 is absent or a hydrophobic separation handle, wherein no more than one of R 1 and G is a hydrophobic separation handle;
L 2 is a carboxyl linking moiety between L on the polymer backbone and B; and
B is a TNF inhibitor.
11. The conjugate of claim 10 , wherein the polymer has from 2 to 100 termini.
12. The conjugate of claim 10 , wherein only one termini of the polymer backbone is covalently bonded to the structure of formula (1).
13. The conjugate of claim 10 , wherein the polymer backbone has two termini.
14. The conjugate of claim 13 , wherein only one termini of the polymer backbone is covalently bonded to the structure of formula (1).
15. The conjugate of claim 13 , wherein both termini of the polymer backbone are covalently bonded to the structure of formula (1).
16. The conjugate of claim 10 , wherein K is selected from the group consisting of: methylene, ethylene, propylene, isopropylene, butylene, isobutylene, sec-butylene, tert-butylene, and hexylene, or a residue from diethylene glycol, triethylene glycol, tetraethylene glycol or hexaethylene glycol.
17. The conjugate of claim 10 , wherein G is a substituted or unsubstituted trityloxy.
18. The conjugate of claim 10 , wherein L is a substituted or unsubstituted C 1 -C 12 alkylene.
19. The conjugate of claim 10 , wherein said polymer backbone is selected from the group consisting of poly(alkylene glycol), poly(oxyethylated polyol), poly(olefinic alcohol), poly(α-hydroxy acid), poly(vinyl alcohol), polyoxazoline, and copolymers.
20. The conjugate of claim 10 , wherein said polymer backbone is poly(ethylene glycol).
21. The conjugate of claim 20 , wherein said poly(ethylene glycol) has an average molecular weight from about 500 Da to about 100,000 Da.
22. A composition comprising the conjugate of claim 10 , and a pharmaceutically acceptable excipient.
23. A method of treating a patient diagnosed with an inflammatory disease, said method comprising administering to said patient an effective amount of the conjugate of claim 10 .
24. The conjugate of claim 10 , wherein said TNF inhibitor is selected from the group consisting of a fusion protein, a monoclonal antibody, and an antibody fragment.
25. The conjugate of claim 10 , wherein said TNF inhibitor is selected from the group consisting of etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab.
26. The composition of claim 22 , wherein said TNF inhibitor is selected from the group consisting of a fusion protein, a monoclonal antibody, and an antibody fragment.
27. The composition of claim 22 , wherein said TNF inhibitor is selected from the group consisting of etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab.